Exploring Regorafenib and Nivolumab as Treatment for Colorectal Cancer
Scott Kopetz, MD, PhD, discusses the combination of regorafenib and nivolumab for patients with colorectal cancerthe combination of regorafenib and nivolumab for patients with colorectal cancer.
Scott Kopetz, MD, PhD, a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the combination of regorafenib (Stivarga) and nivolumab (Opdivo) for patients with colorectal cancer (CRC).
Kopetz says that this combination is a treatment of interest in the CRC landscape right now based on an early phase study that was done in Japan, which showed a high response rate of above 30%. This included patients with metastatic CRC who were microsatellite stable.
There are other similar ongoing phase II trials from single institutions as well as multicenter studies to further evaluate these findings and confirm the data that has been published so far, and Kopetz says he is looking forward to seeing these data published. He believes that there is a lot of hope from physicians in this setting that the regorafenib and nivolumab combination will be beneficial for patients with CRC. There is also an awareness from these physicians that there will need to be more studies to replicate the data in a larger population to better define the benefits of the combination.
